As filed with the Securities and Exchange Commission on March 16, 2018
Registration No.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ACTINIUM PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
| DELAWARE | 74-2963609 | |
| (State or other Jurisdiction of | (I.R.S Employer | |
| Incorporation or Organization) | Identification Number) | |
| 275 Madison Avenue, 7th Floor, New York, NY | 10016 | |
| (Address of Principal Executive Offices) | (Zip Code) |
ACTINIUM PHARMACEUTICALS, INC.
AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN
(Full Title of the Plan)
Sandesh
Seth
Chairman and CEO
275 Madison Avenue, 7th Floor
New York, New York 10016
Phone: (646) 677-3870
(Name, Address and Telephone Number of Agent for Service)
Copy to:
Thomas Slusarczyk, Esq.
The Matt Law Firm, PLLC
1701 Genesee Street
Utica, New York 13501
(315) 235-2299
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer ☐ | Accelerated filer ☒ | |
| Non-accelerated filer ☐ | Smaller reporting company ☐ | |
| (Do not check if a smaller reporting company) | Emerging Growth Company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
| Title of of securities to be registered | Amount to be registered (1) | Proposed maximum offering price per share (2) | Proposed maximum aggregate offering price (2) | Amount of registration fee | ||||||||||||
| Common Stock $0.001 par value (3) | 5,000,000 | $ | 0.43 | $ | 2,150,000 | $ | 267.68 | |||||||||
(1) This Registration Statement also covers additional shares of Actinium Pharmaceuticals, Inc. common stock that may be issuable by reason of stock splits, stock dividends, or other adjustment provisions of the Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan, as amended, in accordance with Rule 416 under the Securities Act of 1933, as amended.
(2) Estimated solely for the purpose of calculating the registration fee computed pursuant to Rule 457(c) and (h), upon the basis of the average of the high and low prices of the common stock as quoted on the NYSE American on March 9, 2018.
(3) Represents the number of stock options and shares available for future option grants under the Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan, as amended.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed by Actinium Pharmaceuticals, Inc. (the “Company”), pursuant to General Instruction E to the Form S-8 Registration Statement under the Securities Act of 1933, as amended, in connection with the registration of an additional 5,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) issuable pursuant to the Company’s Amended and Restated 2013 Stock Plan (as amended, the “Plan”). 12,750,000 shares of Common Stock issuable under the Plan have been previously registered pursuant to the Company’s Registration Statements on Form S-8 (File No. 333-197283 and File No. 333-216746) filed with the Securities and Exchange Commission on July 7, 2014 and March 16, 2017, respectively. and the information contained therein is incorporated herein by reference.
| 1 |
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in accordance with Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. Such documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 3. | Incorporation of Documents by Reference. |
The following documents filed by the Registrant with the Commission are incorporated herein by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):
(a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Commission on March 16, 2018;
(b) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 8, 2018, February 8, 2018, February 15, 2018, February 26. 2018 and March 9, 2018;
(c) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, subsequent to the end of the fiscal year covered by the form referred to in (a) above; and
(d) The description of our common stock, which is contained in our Form 8-K/A, filed with the Securities and Exchange Commission on January 28, 2013, including any amendment or report filed for the purpose of updating such description.
In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.
| 2 |
You may request a copy of these filings, at no cost, by writing or telephoning the Registrant at:
275 Third Avenue
7th Floor
New York, NY 10016
Telephone: 646-677-3870
Attn: Investor Relations
You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.
| Item 8. | Exhibits. |
| * | Filed herewith |
| 3 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 16th day of March, 2018.
| Actinium Pharmaceuticals, Inc. | |||
| By: | /s/ Sandesh Seth | ||
| Name: | Sandesh Seth | ||
| Title: | Chairman
& Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) | ||
Each of the undersigned directors and officers of Actinium Pharmaceuticals, Inc., a Delaware corporation, do hereby constitute and appoint Sandesh Seth the undersigned’s true and lawful attorney and agent, with full power of substitution and resubstitution in each, to do any and all acts and things in our name and on our behalf in our respective capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents, or either one of them, may deem necessary or advisable to enable said corporation to comply with the Securities Act, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this registration statement, including specifically, but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments (including post-effective amendments) hereto, and each of the undersigned does hereby ratify and confirm all that said attorneys and agents, or either one of them or any substitute, shall do or cause to be done by virtue hereof. This Power of Attorney may be executed in any number of counterparts.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
| Signature | Title | Date | ||
| /s/ Sandesh Seth | Chairman and Chief Executive Officer | March 16, 2018 | ||
| Sandesh Seth | (Principal Executive Officer) | |||
| /s/ Steve O’Loughlin | Principal Financial Officer | March 16, 2018 | ||
| Steve O’Loughlin | (Principal Financial and Accounting Officer) | |||
| /s/ David Nicholson | Director | March 16, 2018 | ||
| David Nicholson | ||||
| /s/ Ajit Shetty | Director | March 16, 2018 | ||
| Ajit Shetty | ||||
| /s/ Richard I. Steinhart | Director | March 16, 2018 | ||
| Richard I. Steinhart |
| 4 |
INDEX TO EXHIBITS
* Filed herewith
5